CTC
RXRX icon

Central Trust Company’s Recursion Pharmaceuticals RXRX Stock Holding History

Central Trust Company’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-150
Closed -$732 – 1609
2025
Q3 		$732 Buy
+150
New +$788 ﹤0.01% 1347

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Central Trust Company's RXRX Position: Q4 2025 in Review

Central Trust Company sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 150 shares — an estimated $732 sold.

Central Trust Company first reported a position in RXRX in Q3 2025 and held it in 1 quarter. The position peaked at $732 in Q3 2025. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

  • Central Trust Company reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Central Trust Company sold 150 Recursion Pharmaceuticals shares in Q4 2025, an estimated $732.
  • Central Trust Company first reported a position in Recursion Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Central Trust Company's Recursion Pharmaceuticals position peaked at $732 in Q3 2025.
  • 333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Central Trust Company's 13F filing for Q4 2025, filed 2 Feb 2026.